Skip to main content
PMC home page
Biochemical Journal logoLink to Biochemical Journal
. 2002 May 15;364(Pt 1):157–163. doi: 10.1042/bj3640157

Novel disease-causing mutations in the dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein structure.

André B P van Kuilenburg 1, Doreen Dobritzsch 1, Rutger Meinsma 1, Janet Haasjes 1, Hans R Waterham 1, Malgorzata J M Nowaczyk 1, George D Maropoulos 1, Guido Hein 1, Hermann Kalhoff 1, Jean M Kirk 1, Holger Baaske 1, Anne Aukett 1, John A Duley 1, Kate P Ward 1, Ylva Lindqvist 1, Albert H van Gennip 1
PMCID: PMC1222557  PMID: 11988088

Abstract

Dihydropyrimidine dehydrogenase (DPD) deficiency is an autosomal recessive disease characterized by thymine-uraciluria in homozygous deficient patients. Cancer patients with a partial deficiency of DPD are at risk of developing severe life-threatening toxicities after the administration of 5-fluorouracil. Thus, identification of novel disease-causing mutations is of the utmost importance to allow screening of patients at risk. In eight patients presenting with a complete DPD deficiency, a considerable variation in the clinical presentation was noted. Whereas motor retardation was observed in all patients, no patients presented with convulsive disorders. In this group of patients, nine novel mutations were identified including one deletion of two nucleotides [1039-1042delTG] and eight missense mutations. Analysis of the crystal structure of pig DPD suggested that five out of eight amino acid exchanges present in these patients with a complete DPD deficiency, Pro86Leu, Ser201Arg, Ser492Leu, Asp949Val and His978Arg, interfered directly or indirectly with cofactor binding or electron transport. Furthermore, the mutations Ile560Ser and Tyr211Cys most likely affected the structural integrity of the DPD protein. Only the effect of the Ile370Val and a previously identified Cys29Arg mutation could not be readily explained by analysis of the three-dimensional structure of the DPD enzyme, suggesting that at least the latter might be a common polymorphism. Our data demonstrate for the first time the possible consequences of missense mutations in the DPD gene on the function and stability of the DPD enzyme.

Full Text

The Full Text of this article is available as a PDF (217.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antonarakis S. E. Recommendations for a nomenclature system for human gene mutations. Nomenclature Working Group. Hum Mutat. 1998;11(1):1–3. doi: 10.1002/(SICI)1098-1004(1998)11:1<1::AID-HUMU1>3.0.CO;2-O. [DOI] [PubMed] [Google Scholar]
  2. Bourgoignie J. J. Natriuretic hormones: comparison of renal effects. Klin Wochenschr. 1987;65 (Suppl 8):14–20. [PubMed] [Google Scholar]
  3. Collie-Duguid E. S., Etienne M. C., Milano G., McLeod H. L. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics. 2000 Apr;10(3):217–223. doi: 10.1097/00008571-200004000-00002. [DOI] [PubMed] [Google Scholar]
  4. Collie-Duguid E. S., Johnston S. J., Powrie R. H., Milano G., Etienne M. C., Rochat B., Watson G. C., McLeod H. L. Cloning and initial characterization of the human DPYD gene promoter. Biochem Biophys Res Commun. 2000 Apr 29;271(1):28–35. doi: 10.1006/bbrc.2000.2593. [DOI] [PubMed] [Google Scholar]
  5. Dobritzsch D., Schneider G., Schnackerz K. D., Lindqvist Y. Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil. EMBO J. 2001 Feb 15;20(4):650–660. doi: 10.1093/emboj/20.4.650. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hagen W. R., Vanoni M. A., Rosenbaum K., Schnackerz K. D. On the iron-sulfur clusters in the complex redox enzyme dihydropyrimidine dehydrogenase. Eur J Biochem. 2000 Jun;267(12):3640–3646. doi: 10.1046/j.1432-1327.2000.01393.x. [DOI] [PubMed] [Google Scholar]
  7. Heggie G. D., Sommadossi J. P., Cross D. S., Huster W. J., Diasio R. B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987 Apr 15;47(8):2203–2206. [PubMed] [Google Scholar]
  8. Lu Z. H., Zhang R., Diasio R. B. Comparison of dihydropyrimidine dehydrogenase from human, rat, pig and cow liver. Biochemical and immunological properties. Biochem Pharmacol. 1993 Sep 1;46(5):945–952. doi: 10.1016/0006-2952(93)90505-q. [DOI] [PubMed] [Google Scholar]
  9. Naguib F. N., el Kouni M. H., Cha S. Enzymes of uracil catabolism in normal and neoplastic human tissues. Cancer Res. 1985 Nov;45(11 Pt 1):5405–5412. [PubMed] [Google Scholar]
  10. Podschun B., Wahler G., Schnackerz K. D. Purification and characterization of dihydropyrimidine dehydrogenase from pig liver. Eur J Biochem. 1989 Oct 20;185(1):219–224. doi: 10.1111/j.1432-1033.1989.tb15105.x. [DOI] [PubMed] [Google Scholar]
  11. Porter D. J., Chestnut W. G., Taylor L. C., Merrill B. M., Spector T. Inactivation of dihydropyrimidine dehydrogenase by 5-iodouracil. J Biol Chem. 1991 Oct 25;266(30):19988–19994. [PubMed] [Google Scholar]
  12. Shiotani T., Weber G. Purification and properties of dihydrothymine dehydrogenase from rat liver. J Biol Chem. 1981 Jan 10;256(1):219–224. [PubMed] [Google Scholar]
  13. Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Gartner F. H., Provenzano M. D., Fujimoto E. K., Goeke N. M., Olson B. J., Klenk D. C. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985 Oct;150(1):76–85. doi: 10.1016/0003-2697(85)90442-7. [DOI] [PubMed] [Google Scholar]
  14. Van Kuilenburg A. B., Van Lenthe H., Tromp A., Veltman P. C., Van Gennip A. H. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin Chem. 2000 Jan;46(1):9–17. [PubMed] [Google Scholar]
  15. Van Kuilenburg A. B., Van Lenthe H., Wanders R. J., Van Gennip A. H. Subcellular localization of dihydropyrimidine dehydrogenase. Biol Chem. 1997 Sep;378(9):1047–1053. doi: 10.1515/bchm.1997.378.9.1047. [DOI] [PubMed] [Google Scholar]
  16. Van Kuilenburg A. B., Vreken P., Abeling N. G., Bakker H. D., Meinsma R., Van Lenthe H., De Abreu R. A., Smeitink J. A., Kayserili H., Apak M. Y. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet. 1999 Jan;104(1):1–9. doi: 10.1007/pl00008711. [DOI] [PubMed] [Google Scholar]
  17. Van Kuilenburg A. B., van Lenthe H., Blom M. J., Mul E. P., Van Gennip A. H. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br J Cancer. 1999 Feb;79(3-4):620–626. doi: 10.1038/sj.bjc.6690097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Vreken P., Van Kuilenburg A. B., Meinsma R., van Gennip A. H. Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W. Hum Genet. 1997 Dec;101(3):333–338. doi: 10.1007/s004390050637. [DOI] [PubMed] [Google Scholar]
  19. Wei X., Elizondo G., Sapone A., McLeod H. L., Raunio H., Fernandez-Salguero P., Gonzalez F. J. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics. 1998 Aug 1;51(3):391–400. doi: 10.1006/geno.1998.5379. [DOI] [PubMed] [Google Scholar]
  20. van Gennip A. H., Abeling N. G., Elzinga-Zoetekouw L., Scholten L. G., van Cruchten A., Bakker H. D. Comparative study of thymine and uracil metabolism in healthy persons and in a patient with dihydropyrimidine dehydrogenase deficiency. Adv Exp Med Biol. 1989;253A:111–118. doi: 10.1007/978-1-4684-5673-8_17. [DOI] [PubMed] [Google Scholar]
  21. van Gennip A. H., Abeling N. G., Vreken P., van Kuilenburg A. B. Inborn errors of pyrimidine degradation: clinical, biochemical and molecular aspects. J Inherit Metab Dis. 1997 Jun;20(2):203–213. doi: 10.1023/a:1005356806329. [DOI] [PubMed] [Google Scholar]
  22. van Kuilenburg A. B., Haasjes J., Meinsma R., Waterham H. R., Vreken P., van Gennip A. H. Dihydropyrimidine dehydrogenase (DPD) deficiency: novel mutations in the DPD gene. Adv Exp Med Biol. 2000;486:247–250. doi: 10.1007/0-306-46843-3_48. [DOI] [PubMed] [Google Scholar]
  23. van Kuilenburg A. B., Haasjes J., Richel D. J., Zoetekouw L., Van Lenthe H., De Abreu R. A., Maring J. G., Vreken P., van Gennip A. H. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000 Dec;6(12):4705–4712. [PubMed] [Google Scholar]
  24. van Kuilenburg A. B., Muller E. W., Haasjes J., Meinsma R., Zoetekouw L., Waterham H. R., Baas F., Richel D. J., van Gennip A. H. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res. 2001 May;7(5):1149–1153. [PubMed] [Google Scholar]
  25. van Lenthe H., van Kuilenburg A. B., Ito T., Bootsma A. H., van Cruchten A., Wada Y., van Gennip A. H. Defects in pyrimidine degradation identified by HPLC-electrospray tandem mass spectrometry of urine specimens or urine-soaked filter paper strips. Clin Chem. 2000 Dec;46(12):1916–1922. [PubMed] [Google Scholar]

Articles from Biochemical Journal are provided here courtesy of The Biochemical Society

RESOURCES